Sensus Healthcare, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US81728J1097
USD
4.02
-0.04 (-0.99%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

73.68 k

Shareholding (Mar 2025)

FII

2.51%

Held by 17 FIIs

DII

87.16%

Held by 12 DIIs

Promoter

0.00%

How big is Sensus Healthcare, Inc.?

22-Jun-2025

As of Jun 18, Sensus Healthcare, Inc. has a market capitalization of 79.64 million, with net sales of 39.49 million and a net profit of 1.81 million over the latest four quarters. The balance sheet shows shareholder's funds of 55.83 million and total assets of 62.19 million.

As of Jun 18, Sensus Healthcare, Inc. has a market capitalization of 79.64 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 39.49 million for the latest four quarters, alongside a net profit of 1.81 million during the same period.<BR><BR>As of Dec 24, the balance sheet shows shareholder's funds amounting to 55.83 million and total assets of 62.19 million.

Read More

What does Sensus Healthcare, Inc. do?

22-Jun-2025

Sensus Healthcare, Inc. is a medical device company specializing in non-invasive treatments for skin conditions, with recent net sales of $8 million and a market cap of $79.64 million. The company reported a net profit of -$3 million for the quarter ending March 2025.

Overview: <BR>Sensus Healthcare, Inc. is a medical device company focused on providing non-invasive treatments for both oncological and non-oncological skin conditions, operating within the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 8 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -3 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 79.64 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 45.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.35 <BR>Return on Equity: 3.40% <BR>Price to Book: 1.50<BR><BR>Contact Details: <BR>Address: 851 Broken Sound Pkwy NW Ste 215, BOCA RATON FL: 33487-3635 <BR>Tel: ['1 561 9225808', '1 212 8383777'] <BR>Fax: 1 561 9482071 <BR>Website: https://sensushealthcare.com/

Read More

Should I buy, sell or hold Sensus Healthcare, Inc.?

22-Jun-2025

Who are in the management team of Sensus Healthcare, Inc.?

22-Jun-2025

As of March 2022, the management team of Sensus Healthcare, Inc. includes Chairman and CEO Joseph Sardano, Directors Megan Cornish and Anthony Petrelli, and Non-Executive Independent Directors John Heinrich, William McCall, and Samuel O'Rear. They are responsible for the company's strategic direction and operations.

As of March 2022, the management team of Sensus Healthcare, Inc. includes the following individuals:<BR><BR>- Mr. Joseph Sardano: Chairman of the Board, President, Chief Executive Officer, Co-Founder<BR>- Ms. Megan Cornish: Director<BR>- Mr. Anthony Petrelli: Non-Employee Director<BR>- Dr. John Heinrich: Non-Executive Independent Director<BR>- Mr. William McCall: Non-Executive Independent Director<BR>- Mr. Samuel O'Rear: Non-Executive Independent Director<BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

Read More

Is Sensus Healthcare, Inc. overvalued or undervalued?

20-Sep-2025

As of August 7, 2025, Sensus Healthcare, Inc. is considered risky and overvalued due to its high P/E ratio of 45 and EV to EBITDA of 20.70, which are significantly higher than its peers like Kewaunee Scientific Corp., while its low ROCE of 7.47% and ROE of 3.40% do not justify its valuation.

As of 7 August 2025, the valuation grade for Sensus Healthcare, Inc. has moved from expensive to risky, indicating a shift in perception regarding its market position. The company appears to be overvalued, given its high P/E ratio of 45 compared to peers and industry standards. Additionally, the EV to EBITDA ratio stands at 20.70, which is significantly higher than Kewaunee Scientific Corp.'s attractive EV to EBITDA of 8.2820, further emphasizing the relative overvaluation of Sensus.<BR><BR>With a ROCE of 7.47% and a ROE of 3.40%, Sensus Healthcare's financial performance does not justify its current valuation metrics. The peer comparison shows that while Sensus is categorized as risky, other companies like Kewaunee Scientific Corp. are considered attractive, highlighting the disparity in valuation. Although return data is not available for a direct comparison with the S&P 500, the current valuation metrics suggest that Sensus Healthcare, Inc. is not positioned favorably in the market.

Read More

Is Sensus Healthcare, Inc. technically bullish or bearish?

20-Sep-2025

As of August 8, 2025, Sensus Healthcare, Inc. is in a bearish trend, supported by bearish MACD, Bollinger Bands, and moving averages, with mixed signals from other indicators.

As of 8 August 2025, the technical trend for Sensus Healthcare, Inc. has changed from mildly bearish to bearish. The current stance is bearish with a strong indication from multiple indicators. The MACD is bearish on both the weekly and monthly time frames, and Bollinger Bands also confirm a bearish outlook for both periods. Daily moving averages are bearish, and the KST is bearish on the weekly and mildly bearish on the monthly. The Dow Theory shows a mildly bullish signal on the weekly but no trend on the monthly, while the OBV is mildly bearish on the weekly. There is no available return data to compare the company's performance against the S&P 500.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

With a fall in Net Sales of -20.82%, the company declared Very Negative results in Jun 25

  • PRE-TAX PROFIT(Q) At USD -1.76 MM has Fallen at -180.33%
  • NET PROFIT(Q) At USD -1.04 MM has Fallen at -164.33%
  • ROCE(HY) Lowest at -1.62%
2

Risky - Market Cap of less than 100 cr

3

Underperformed the market in the last 1 year

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 53 Million (Micro Cap)

stock-summary
P/E

45.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.42

stock-summary
Return on Equity

-1.63%

stock-summary
Price to Book

1.02

Revenue and Profits:
Net Sales:
7 Million
(Quarterly Results - Jun 2025)
Net Profit:
-1 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
23.69%
0%
23.69%
6 Months
-16.77%
0%
-16.77%
1 Year
-53.15%
0%
-53.15%
2 Years
65.43%
0%
65.43%
3 Years
-39.91%
0%
-39.91%
4 Years
-42.74%
0%
-42.74%
5 Years
20.0%
0%
20.0%

Sensus Healthcare, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
16.90%
EBIT Growth (5y)
12.13%
EBIT to Interest (avg)
3.88
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.36
Sales to Capital Employed (avg)
0.68
Tax Ratio
47.93%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
35.37%
ROCE (avg)
29.00%
ROE (avg)
15.24%
Valuation key factors
Factor
Value
P/E Ratio
45
Industry P/E
Price to Book Value
1.53
EV to EBIT
24.43
EV to EBITDA
20.70
EV to Capital Employed
1.83
EV to Sales
1.58
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
7.47%
ROE (Latest)
3.40%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 12 Schemes (10.19%)

Foreign Institutions

Held by 17 Foreign Institutions (2.51%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -20.65% vs 104.44% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -162.50% vs 500.00% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "7.30",
          "val2": "9.20",
          "chgp": "-20.65%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.80",
          "val2": "2.10",
          "chgp": "-185.71%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.00",
          "val2": "1.60",
          "chgp": "-162.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-265.60%",
          "val2": "214.50%",
          "chgp": "-48.01%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 71.31% vs -45.17% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 1,220.00% vs -97.93% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "41.80",
          "val2": "24.40",
          "chgp": "71.31%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "8.50",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "6.60",
          "val2": "0.50",
          "chgp": "1,220.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "193.50%",
          "val2": "-15.70%",
          "chgp": "20.92%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
7.30
9.20
-20.65%
Operating Profit (PBDIT) excl Other Income
-1.80
2.10
-185.71%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-1.00
1.60
-162.50%
Operating Profit Margin (Excl OI)
-265.60%
214.50%
-48.01%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is -20.65% vs 104.44% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -162.50% vs 500.00% in Jun 2024

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
41.80
24.40
71.31%
Operating Profit (PBDIT) excl Other Income
8.50
0.00
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
6.60
0.50
1,220.00%
Operating Profit Margin (Excl OI)
193.50%
-15.70%
20.92%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 71.31% vs -45.17% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 1,220.00% vs -97.93% in Dec 2023

stock-summaryCompany CV
About Sensus Healthcare, Inc. stock-summary
stock-summary
Sensus Healthcare, Inc.
Pharmaceuticals & Biotechnology
Sensus Healthcare, Inc. is a medical device company. The Company is focused on providing non-invasive treatments for both oncological and non-oncological skin conditions. It uses a low-energy X-ray technology known as superficial radiation therapy (SRT). The Company incorporated SRT into its portfolio of treatment devices: the SRT-100, SRT-100 Plus and SRT-100 Vision. The Company's product, the SRT-100, is a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers and other skin conditions, such as keloids. The SRT-100 treats primary lesions in the sensitive areas of the head and neck region. Its Sensus Laser Aesthetic Solutions division provides a range of in-office aesthetic dermatology procedures including facial rejuvenation, wrinkle removal, body sculpting/fat removal as well as other aesthetic applications.
Company Coordinates stock-summary
Company Details
851 Broken Sound Pkwy NW Ste 215 , BOCA RATON FL : 33487-3635
stock-summary
Tel: 1 561 92258081 212 8383777
stock-summary
Registrar Details